Lung Transplantation for Patients with Cystic Fibrosis and Achromobacter xylosoxidans in the Lung Allocation Score Era
Lung transplantation is an accepted therapy for patients with end stage lung disease due to Cystic Fibrosis (CF). Up to ten percent of patients with CF are colonized with Achromobacter xylosoxidans, a gram negative organism that due to its intrinsic resistance to many antibiotics may affect negatively impact post-transplant outcomes.
In this study they also showed PTX3 localized in NETs formed after neutrophil activation (5). Proteomics analysis revealed that PTX3 forms complexes with two anti-microbial proteins [azurocidin (AZU1) and myeloperoxidase (MPO)] associated to NETs (30). More recently, PTX3 localization in NETs has been confirmed, and the colocalization with AZU1 and MPO has been defined more accurately (31). Further investigation will be needed to understand the involvement of PTX3 interaction with AZU1 and MPO in their antibacterial role during NET formation. Regulation of Complement Activation PTX3 interaction with microorganisms is not...
CONCLUSIONS Lung transplantation improves respiratory capacity of CF patients and prolongs their life. PMID: 30948702 [PubMed - in process]
We report practice patterns and outcomes for pediatric LTx in CF and non-CF patients.
Bacteriophages are host-specific lytic viruses that are of increasing interest as adjunctive therapy for treatment of multi-drug resistant (MDR) pathogens.
The primary driver of poor outcomes in the early stages of lung transplantation is primary graft dysfunction (PGD). Patients with cystic fibrosis (CF) have unique physiology and demographics compared to other lung transplant recipients. Therefore, we sought to identify risk factors for PGD in the CF patient population undergoing lung transplantation.
Exophiala dermatitidis is a black fungus that frequently colonises the lungs of people with cystic fibrosis (CF). Mucoid and non-mucoid variants can be detected from the same sputum for some patients, but their role in chronic CF lung disease is not fully understood and attempts at early eradication are not routinely performed. Invasive infections with this species are rare; however in 2014 we reported our first case of fatal, invasive infection with a highly mucoid strain of E. dermatitidis in a 34 year old post lung transplant patient with CF.
This study, in a project funded by the Cystic Fibrosis Lung Transplant Consortium, examined candidates understanding and concerns in each of these domains.
Distal intestinal obstruction syndrome (DIOS) is a debilitating condition which is unique to Cystic Fibrosis (CF). Constipation is increasingly common in CF patients as a result of the altered fluid composition of the intestine caused by the CF transmembrane conductance regulator gene defect. The incidence of both DIOS and constipation is increased in CF-patients post lung transplant1-2.
To identify novel variables associated with waitlist (WL) and posttransplant (PT) mortality for cystic fibrosis (CF) lung transplant patients. To analyze the impact of including new variables in the lung allocation score (LAS) system.
The objective of these guidelines is to provide recommendations to the CF community to enhance identification and timely referral of individuals with CF who could benefit from LTx, as well as to encourage partnerships between CF Centers and LTx Centers to improve the referral process.